Wie hoch ist der Preis für Accelerate Diagnostics, Inc. (AXDX)

Preis für Accelerate Diagnostics, Inc. (AXDX) ist $0.01005

Wie hoch ist die Marktkapitalisierung für Accelerate Diagnostics, Inc. (AXDX)

Marktkapitalisierung für Accelerate Diagnostics, Inc. (AXDX) ist $146.42K

Accelerate Diagnostics, Inc. (AXDX) Operative Marge

Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.

Jahr	Operative Marge	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Operative Marge

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Operative Marge	Differenz der operativen Marge	Land
Abbott Laboratories ABT.US	17.03%	-	US
Stryker Corporation SYK.US	22.03%	-	US
Medtronic plc MDT.US	17.86%	-	IE
Boston Scientific Corporation BSX.US	21.46%	-	US
Edwards Lifesciences Corporation EW.US	28.09%	-	US

Unternehmen

Operative Marge

Differenz der operativen Marge

Land